ABBV - AbbVie reports positive results from Rinvoq versus Dupixent study
2024-04-25 11:24:05 ET
More on AbbVie
- AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment
- AbbVie: Through Humira's Crisis Towards Solid Growth
- AbbVie: Great To Be Proven Wrong - Still Not A Buy
- AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1
- AbbVie breaks six day winning cycle, trades in the red